

USPTO PATENT FULL-TEXT AND IMAGE DATABASE

Home	Quick	Advanced	Pat Num	Help
Next List		Bottom	View Cart	

Searching 1976 to present...

Results of Search in 1976 to present db for:

(ACLM/"peptide consisting essentially of" OR ACLM/"polypeptide consisting essentially of"):
165 patents.

Hits 1 through 50 out of 165


[Next 50 Hits](#)


[Jump To](#)

[Refine Search](#)

PAT. NO.	Title
1 7,005,419	T Methods for identifying inhibitors of GADD45 polypeptide activity and inhibitors of such activity
2 6,977,144	T Sid nucleic acids and polypeptides selected from a pathogenic strain of hepatitis C virus and applications thereof
3 6,964,855	T Peptides for detection to Anaplasma phagocytophilum
4 6,955,891	T Reagents for assaying Bacillus anthracis lethal factor protease
5 6,951,652	T Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases
6 6,923,965	T Modulators of polysaccharides and uses thereof
7 6,916,607	T PEPTIDES AND POLYPEPTIDES DERIVED FROM THE SUBMAXILLARY GLAND OF THE RAT CORRESPONDING POLYCLONAL AND MONOCLONAL ANTIBODIES CORRESPONDING HYBRIDOMAS AND USES OF THESE PRODUCTS FOR DIAGNOSIS FOR DETECTION OR THERAPEUTIC PURPOSES
8 6,916,604	T Uses of synthetic peptides corresponding to telopeptide sequences of cross-linked type I collagen metabolites
9 6,855,317	T Immunological herpes simplex virus antigens and methods for use thereof
10 6,841,360	T Nucleotide sequences coding for the export of branched-chain amino acids, process for the isolation thereof and use thereof
11 6,825,029	T Nucleotide sequences which code for the opcA gene
12 6,825,005	T Methods and reagents to regulate apoptosis
13 6,821,723	T GP41 antigen

- 14 [6,806,060](#) **T** [Methods for the identification of inhibitors of threonine synthase as antibiotics](#)
- 15 [6,783,953](#) **T** [Vascular endothelial growth factor-X](#)
- 16 [6,767,887](#) **T** [Exendin analogues, processes for their preparation and medicaments containing them](#)
- 17 [6,759,211](#) **T** [Tumor growth inhibition- and apoptosis-associated genes and polypeptides and methods of use thereof](#)
- 18 [6,734,287](#) **T** [Specific binding proteins for treating canine allergy](#)
- 19 [6,733,757](#) **T** [Adeno-associated virus capsid immunologic determinants](#)
- 20 [6,723,529](#) **T** [Methods for the identification of inhibitors of .alpha.-aminoadipate reductase as antibiotics](#)
- 21 [6,716,624](#) **T** [GSK3 polypeptides](#)
- 22 [6,716,452](#) **T** [Active agent delivery systems and methods for protecting and administering active agents](#)
- 23 [6,706,495](#) **T** [Staphylococcal GTPase obg nucleotide sequence encoding Staphylococcal GTP-binding protein](#)
- 24 [6,699,477](#) **T** [EBV CTL epitopes](#)
- 25 [6,696,546](#) **T** [Peptide that kills growing but not stationary cells](#)
- 26 [6,686,444](#) **T** [Osteopontin derived chemotactic peptides and methods of use](#)
- 27 [6,660,488](#) **T** [Antibodies for the alpha platelet-derived growth factor receptor](#)
- 28 [6,653,285](#) **T** [Modulators of polysaccharides and uses thereof](#)
- 29 [6,641,814](#) **T** [Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis](#)
- 30 [6,632,631](#) **T** [Methods for the identification of inhibitors of homocitrate synthase as antibiotics](#)
- 31 [6,630,618](#) **T** [Transgenic plants having non-pathogen induced systemic acquired resistance \(SAR\)](#)
- 32 [6,613,545](#) **T** [Nucleotide sequences coding for the export of branched chain amino acids, process for the isolation thereof and use thereof](#)
- 33 [6,586,401](#) **T** [Troponin subunit I fragment and homologs thereof](#)
- 34 [6,570,000](#) **T** [DNA encoding the T cell surface protein CD4 and use of fragments of CD4 in the treatment of AIDS](#)
- 35 [6,558,950](#) **T** [Methods and reagents for modulating apoptosis](#)
- 36 [6,548,743](#) **T** [Transgenic plants expressing a dual-specificity MAPK phosphatase and uses thereof](#)
- 37 [6,548,642](#) **T** [Synthetic genes for plant gums](#)
- 38 [6,537,965](#) **T** [Amino-terminal modified parathyroid hormone \(PTH\) analogs](#)
- 39 [6,517,845](#) **T** [Mycobacterium tuberculosis superoxide dismutase](#)
- 40 [6,509,017](#) **T** [66 KDA antigen from Borrelia](#)
- 41 [6,506,553](#) **T** [Method for diagnosis of Epstein-Barr virus associated disease](#)
- 42 [6,489,540](#) **T** [Plastid-targeting nucleic acid sequence, a novel .beta.-amylase sequence, a stimulus-responsive promoter and uses thereof](#)
- 43 [6,489,137](#) **T** [Detection of loss of the wild-type huBUB1 gene](#)
- 44 [6,458,528](#) **T** [Diagnosis of feline immunodeficiency virus infection using ENV/GAG polypeptide markers](#)
- 45 [6,458,357](#) **T** [Retro-inverso neurotrophic and analgesic peptides](#)
- 46 [6,437,112](#) **T** [Materials for the production of nanometer structures and use thereof](#)
- 47 [6,432,677](#) **T** [Non-human animal interferons](#)
- 48 [6,417,333](#) **T** [Modified human parathyroid hormone](#)

49 [6,399,328](#)  [Methods and compositions for diagnosis and treatment of breast cancer](#)

50 [6,395,875](#)  [Recombinant soluble adenovirus receptor](#)

	Next List	Top	View Cart	
Home	Quick	Advanced	Pat Num	Help

USPTO PATENT FULL-TEXT AND IMAGE DATABASE

Home	Quick	Advanced	Pat Num	Help
Prev. List	Next List	Bottom	View Cart	

Searching 1976 to present...

Results of Search in 1976 to present db for:

(ACLM/"peptide consisting essentially of" OR ACLM/"polypeptide consisting essentially of"):
165 patents.

Hits 51 through 100 out of 165

[Prev. 50 Hits](#)


[Next 50 Hits](#)

[Jump To](#)

[Refine Search](#)

PAT. NO.	Title
51 6,372,720	T Liposome fusion and delivery vehicle
52 6,355,610	T Inhibitors of formation of protease resistant prion protein
53 6,355,442	T METHOD OF ASSAYING COLLAGEN FRAGMENTS IN BODY FLUIDS, A TEST KIT AND MEANS FOR CARRYING OUT THE METHOD AND USE OF THE METHOD TO DIAGNOSE THE PRESENCE OF DISORDERS ASSOCIATED WITH THE METABOLISM OF COLLAGEN
54 6,342,361	T Method of assaying collagen fragments in body fluids, a test kit and means for carrying out the same
55 6,319,504	T Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
56 6,242,577	T Isolation and use fibronectin receptor
57 6,239,101	T Thrombin binding polypeptides
58 6,232,110	T Coding sequence for protein phosphatase methylesterase, recombinant DNA molecules and methods
59 6,211,149	T Inhibitors of formation of protease resistant prion protein
60 6,210,676	T Compositions and methods using the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein C (OspC) for the diagnosis and prevention of lyme disease
61 6,204,363	T Stem cell factor
62 6,203,798	T Borrelia antigen

- 63 [6,197,588](#) **T** [Plastid inner envelope membrane targeting polypeptides, manufacture and use thereof](#)
- 64 [6,184,346](#) **T** [Protease inhibitors derived from guamerin](#)
- 65 [6,150,137](#) **T** [Immunosuppressant target proteins](#)
- 66 [6,143,509](#) **T** [Prostate specific antigen peptides and uses thereof](#)
- 67 [6,130,070](#) **T** [Induction promoter gene and secretory signal gene usable in Schizosaccharomyces pombe, expression vectors having the same, and use thereof](#)
- 68 [6,127,521](#) **T** [Immunosuppressant target proteins](#)
- 69 [6,114,145](#) **T** [Synferon, a synthetic interferon](#)
- 70 [6,110,689](#) **T** [Method of assaying collagen fragments in body fluids, a test kit and means for carrying out the method and use of the method to diagnose the presence of disorders associated with the metabolism of collagen](#)
- 71 [6,100,379](#) **T** [Synthetic peptides corresponding to telopeptide sequences of cross-linked type II collagen metabolites](#)
- 72 [6,057,104](#) **T** [Disruption of the mammalian Rad51 protein and disruption of proteins that associate with mammalian Rad51 for hindering cell proliferation](#)
- 73 [5,993,819](#) **T** [Synthetic vaccine for protection against human immunodeficiency virus infection](#)
- 74 [5,908,832](#) **T** [Peptide analog](#)
- 75 [5,892,019](#) **T** [Production of a single-gene-encoded immunoglobulin](#)
- 76 [5,874,531](#) **T** [Identification of self and non-self antigens implicated autoimmune disease](#)
- 77 [5,864,013](#) **T** [Materials for the production of nanometer structures and use thereof](#)
- 78 [5,864,011](#) **T** [Cancer related antigen](#)
- 79 [5,837,692](#) **T** [Inhibition of the mitogenic activity of PDGF by mammalian EGr](#)
- 80 [5,795,718](#) **T** [Detection of complementary nucleotide sequences](#)
- 81 [5,770,693](#) **T** [Calpain-inhibiting peptide analogs of the kininogen heavy chain](#)
- 82 [5,720,959](#) **T** [Malaria vaccine](#)
- 83 [5,695,762](#) **T** [Immunodominant sites of HTLV-I envelope protein](#)
- 84 [5,668,002](#) **T** [DNA and polypeptide for tumor-associated antigen CO-029](#)
- 85 [5,663,294](#) **T** [Calpain-inhibiting peptide analogs of the kininogen heavy chain](#)
- 86 [5,644,031](#) **T** [Delta-like gene expressed in neuroendocrine tumors](#)
- 87 [5,604,117](#) **T** [Antibodies to Plasmodium falciparum](#)
- 88 [5,599,681](#) **T** [Activation-state-specific phosphoprotein immunodetection](#)
- 89 [5,545,727](#) **T** [DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin](#)
- 90 [5,540,933](#) **T** [Isolation and use of fibronectin receptor](#)
- 91 [5,494,672](#) **T** [Pseudomonas peptide composition and method](#)
- 92 [5,482,931](#) **T** [Stabilized pharmaceutical peptide compositions](#)
- 93 [5,374,520](#) **T** [Assay method for Epstein-Barr virus antibodies](#)
- 94 [5,367,060](#) **T** [Structure, production and use of heregulin](#)
- 95 [5,356,775](#) **T** [Primary structure for functional expression from complementary DNA of a mammalian ATP-sensitive potassium channel](#)
- 96 [5,352,664](#) **T** [Thrombin derived polypeptides; compositions and methods for use](#)
- 97 [5,348,740](#) **T** [Antigenic polypeptides of Taenia ovis](#)
- 98 [5,342,921](#) **T** [Superoxide dismutase fusion polypeptides for expression of mammalian proteins](#)

99 [5,336,758](#)  [Peptides stimulating cytotoxic T cells immune to HIV RT](#)

100 [5,330,911](#)  [Surfaces having desirable cell adhesive effects](#)

[Prev. List](#)

[Next List](#)

[Top](#)

[View Cart](#)

[Home](#)

[Quick](#)

[Advanced](#)

[Pat Num](#)

[Help](#)

USPTO PATENT FULL-TEXT AND IMAGE DATABASE

Home	Quick	Advanced	Pat Num	Help
Prev. List	Next List	Bottom	View Cart	

Searching 1976 to present...

Results of Search in 1976 to present db for:

(ACLM/"peptide consisting essentially of" OR ACLM/"polypeptide consisting essentially of"):
165 patents.

Hits 101 through 150 out of 165

Prev. 50 Hits

Final 15 Hits

Jump To

Refine Search

aclm/("peptide consisting essentially of") or aclm/("pol

PAT. NO.	Title
101 5,328,898	T Factor XIIIa fibrin binding fragments
102 5,312,901	T Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
103 5,312,810	T Method and compositions for making ACSF and ACSF antagonists
104 5,310,876	T Expression of HIV1 and HIV2 polypeptides and their use
105 5,310,874	T Integrin .alpha. subunit cytoplasmic domain polypeptides and antibodies
106 5,300,630	T Oncofetal fibronectin epitope
107 5,280,106	T Matrix metalloproteinase peptides: role in diagnosis and therapy
108 5,278,063	T Chemical modification of promote animal cell adhesion on surfaces
109 5,273,884	T Polypeptides, antigens or vaccines protective against babesiosis
110 5,260,274	T Factor VIII binding domain of von Willebrand Factor
111 5,260,208	T Enantioselective amidases, DNA sequences encoding them, method of preparation and utilization
112 5,256,768	T Expression of antigenic Epstein-Barr virus polypeptides in bacteria and their use in diagnostics
113 5,229,491	T Peptides immunochemically reactive with antibodies directed against hepatitis Non-A, Non-B virus
114 5,227,466	T Insulin receptor binding site
115 5,223,606	T Steroid/thyroid hormone receptor-related protein inappropriately expressed in human

hepatocellular carcinoma

- 116 5,221,619 **T** Method and means for microbial polypeptide expression
- 117 5,219,748 **T** Recombinant human and rat protein kinase C polypeptides
- 118 5,219,566 **T** Immunoprophylactic polypeptides for schistosomiasis
- 119 5,217,898 **T** Expression of the P. falciparum transmission-blocking antigen in yeast
- 120 5,212,083 **T** Sequence for stabilizing proteins in bacteria
- 121 5,210,180 **T** Enhancement of porcine somatotropin activity
- 122 5,206,347 **T** Isolation and use of receptors binding to a peptide column
- 123 5,204,446 **T** Polypeptide having immunoreactivity with antibody specific to hepatitis B virus
- 124 5,200,510 **T** Method for purifying factor VIII:C, von Willebrand factor and complexes thereof
- 125 5,198,425 **T** Inhibitors of bacterial ribonucleotide reductase
- 126 5,190,919 **T** Antihemostatic Factor VII peptides
- 127 5,179,081 **T** Method of treatment using an anticoagulant polypeptide
- 128 5,177,188 **T** Methods and compositions for diagnosing chronic immune thrombocytopenic purpura
- 129 5,171,843 **T** Immunogenic polypeptide and method for purifying it
- 130 5,165,925 **T** Vaccine for immunizing fish against infectious pancreatic necrosis virus
- 131 5,157,020 **T** Synthetic senescent cell antigen
- 132 5,143,726 **T** T cell epitopes of the hepatitis B virus nucleocapsid protein
- 133 5,130,415 **T** Synthetic peptide endowed with immunological activity, capable of inducing the production of antibodies with a high specificity towards alpha-fetoprotein, and their use in the diagnostic field
- 134 5,124,439 **T** Antibodies against fibrin; immunogenic peptides suitable for preparing the antibodies, method for determining fibrin and pharmaceutical preparation based on the antibodies
- 135 5,115,097 **T** Synthetic peptide from the carboxy terminal of human Mn-superoxide dismutase
- 136 5,112,945 **T** Preparation of islet amyloid polypeptides (IAPP) and antibodies to IAPP
- 137 5,106,954 **T** Erythropoietin (EPO) peptides
- 138 5,106,760 **T** ATCC HB8209, its monoclonal antibody to erythropoietin and assay using same
- 139 5,079,228 **T** Peptide inhibitors of neutrophil activating factor induced chemotaxis
- 140 5,055,396 **T** Diagnostic methods and systems for quantifying APO AI
- 141 5,051,254 **T** Immunoprophylactic polypeptides for schistosomiasis
- 142 5,049,655 **T** Melanin-concentrating hormones
- 143 5,028,425 **T** Synthetic vaccine against P. falciparum malaria
- 144 5,019,387 **T** Production of antibodies to HIV
- 145 5,007,925 **T** Prosthetic devices coated with polypeptides with type IV collagen activity
- 146 4,988,621 **T** Peptides in cell detachment and aggregation
- 147 4,981,956 **T** DNA sequences encoding bovine growth factors
- 148 4,981,950 **T** Vasoconstrictor peptide
- 149 4,957,869 **T** Immunogenic peptide corresponding to P. vivax CS protein
- 150 4,886,782 **T** Malarial immunogen

[Prev. List](#)

[Next List](#)

[Top](#)

[View Cart](#)

USPTO PATENT FULL-TEXT AND IMAGE DATABASE

Home	Quick	Advanced	Pat Num	Help
Prev. List	Bottom	View Cart		

Searching 1976 to present...

Results of Search in 1976 to present db for:

(ACLM/"peptide consisting essentially of" OR ACLM/"polypeptide consisting essentially of"):
165 patents.

Hits 151 through 165 out of 165

[Prev. 50 Hits](#)

[Jump To](#)

[Refine Search](#)

PAT. NO.	Title
151 4,882,145	T T cell epitopes of the hepatitis B virus nucleocapsid protein
152 4,879,237	T Use of peptides in control of cell attachment and detachment
153 4,879,213	T Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
154 4,818,527	T T cell epitopes of the hepatitis B virus nucleocapsid protein
155 4,783,524	T Growth factors
156 4,769,235	T Immunodominant epitope of the circumsporozoite surface protein
157 4,762,881	T Photoreactive benzoylphenylalanines and related peptides
158 4,743,554	T Recombinant DNA expression vector encoding for foot and mouth disease virus proteins
159 4,736,017	T Chemically defined vaccine against urinary infections
160 4,683,136	T Proteinaceous antigens with conformation-independent and conformation-dependent determinants
161 4,578,217	T Synthetic antigenic peptide derived from hepatitis B surface antigen
162 4,575,495	T Synthetic antigenic peptide derived from Hepatitis B surface antigen
163 4,518,527	T Polypeptides related to the pre-acetylcholine receptor-.alpha. of the electric organ of Torpedo californica
164 4,414,150	T Hybrid human leukocyte interferons
165 4,212,650	T Diagnostic process